283 related articles for article (PubMed ID: 23429289)
1. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
2. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
[TBL] [Abstract][Full Text] [Related]
3. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
4. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
[TBL] [Abstract][Full Text] [Related]
5. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pejenaute-Ochoa D; Jarauta V; Marzo I; Fernández LJ; Ochoa I; Conde B; Anel A; Martinez-Lostao L
Cancer Lett; 2016 Dec; 383(2):250-260. PubMed ID: 27725224
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
8. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.
Gupta SC; Reuter S; Phromnoi K; Park B; Hema PS; Nair M; Aggarwal BB
J Biol Chem; 2011 Jan; 286(2):1134-46. PubMed ID: 21078664
[TBL] [Abstract][Full Text] [Related]
9. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
[TBL] [Abstract][Full Text] [Related]
11. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
[TBL] [Abstract][Full Text] [Related]
12. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5.
Lee YS; Lee DH; Jeong SY; Park SH; Oh SC; Park YS; Yu J; Choudry HA; Bartlett DL; Lee YJ
J Cell Biochem; 2019 Jan; 120(1):928-939. PubMed ID: 30160785
[TBL] [Abstract][Full Text] [Related]
14. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
15. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
[TBL] [Abstract][Full Text] [Related]
16. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
[TBL] [Abstract][Full Text] [Related]
17. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
18. Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade.
Huang KC; Chiang SF; Chang HY; Chen WT; Yang PC; Chen TW; Liang JA; Shiau AC; Ke TW; Clifford Chao KS
Cell Death Dis; 2022 Jul; 13(7):610. PubMed ID: 35835756
[TBL] [Abstract][Full Text] [Related]
19. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
